Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 2/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18398130 | 0.86 | GSK3B (0.53) | GSK3BTSHRPTPN1KMOALDH1A1 | |
| SCHEMBL29514695 | 0.81 | GSK3B (0.61) | GSK3BTSHRPTPN1SRD5A2KMO | |
| SCHEMBL747174 | 0.81 | GSK3B (0.61) | GSK3BTSHRPTPN1SRD5A2KMO | |
| SCHEMBL30162746 | 0.81 | TSHR (0.68) | TSHRCASP1SMN1; SMN2PTPN1SRD5A2 | |
| SCHEMBL68294 | 0.81 | TSHR (0.68) | TSHRCASP1SMN1; SMN2PTPN1SRD5A2 | |
| SCHEMBL31386348 | 0.80 | GSK3B (0.47) | GSK3BCASP1SMN1; SMN2PTPN1ALDH1A1 | |
| SCHEMBL11826250 | 0.80 | GSK3B (0.47) | GSK3BSMN1; SMN2PTPN1NR1H4ALDH1A1 | |
| SCHEMBL16056966 | 0.80 | GSK3B (0.55) | GSK3BPTPN1NR1H4MYCALDH1A1 | |
| Bromide SCHEMBL5722043 | 0.79 | GSK3B (0.59) | GSK3BTSHRPTPN1SRD5A2KMO | |
| Hydrochloric Acid SCHEMBL1681859 | 0.79 | TSHR (0.65) | TSHRCASP1SMN1; SMN2PTPN1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491741-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20070155671-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER | 2007-07-05 | — | — | US | disclosed |
| US-7217728-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050080119-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2005-04-14 | — | — | US | disclosed |
| US-6803384-B2 | FOR THERAPY OF REPERFUSION INJURY | HOFFMANN-LA ROCHE INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040006236-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2004-01-08 | — | — | US | disclosed |
| US-6515124-B2 | (Z)-2-((2-bromo-4-(((3-hydroxybenzyl)amino)carbonyl)benzoyl) -amino)pent-2-enoic acid, for example; useful for treating psoriasis | HOFFMAN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1261579-A1 | DEHYDROAMINO ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20020161237-A1 | Dehydroamino acids | HOFFMANN-LA ROCHE INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020052512-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2002-05-02 | — | — | US | disclosed |
| US-6331640-B1 | TREATMENT OF REPERFUSION INJURIES | HOFFMANN-LA ROCHE INC. | 2001-12-18 | — | — | US | disclosed |
| WO-2001058853-A1 | DEHYDROAMINO ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-16 | — | — | WO | disclosed |
| EP-1121342-A1 | DIAMINOPROPIONIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000021920-A1 | DIAMINOPROPIONIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161237-A1 | Dehydroamino acids | HSD3B1, CYP8B1, TH | GSK3B 2005/4885TSHR 1248/4885CASP1 567/4885 |
| US-20040006236-A1 | Diaminopropionic acid derivatives | AIFM1, AIFM2, HIF1A | GSK3B 3205/4885TSHR 2834/4885CASP1 7/4885 |
| US-20020052512-A1 | Diaminopropionic acid derivatives | AIFM1, AIFM2, HIF1A | GSK3B 3205/4885TSHR 2834/4885CASP1 7/4885 |
| US-20070155671-A1 | Diaminopropionic acid derivatives | AIFM1, HIF1A, AIFM2 | GSK3B 2878/4885TSHR 2665/4885CASP1 37/4885 |
| US-20050080119-A1 | Diaminopropionic acid derivatives | AIFM1, HIF1A, AIFM2 | GSK3B 2878/4885TSHR 2665/4885CASP1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.